News

Mavenclad is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active RMS, including disability progression, annualized relapse rate

The Humira biosimilar can now be used in Europe for treating rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis

As per terms of the transaction, Regenxbio will pay $3.41 per Dimension share, which could be valued at around $86m. The acquisition will add Regenxbio with two product

Ribociclib is now licensed for use in Europe as a first-line treatment in combination with an aromatase inhibitor in postmenopausal women with hormone receptor positive, human epidermal growth

The bispecific monoclonal antibody is intended to be used as a once-weekly subcutaneous treatment for the disease to cover adults, adolescents and children. According to Roche, emicizumab binds

At 12 months, APL-2, administered monthly via intravitreal injection, showed a 29% (p=0.008) reduction in the rate of GA lesion growth compared to sham. With every other month

"New drugs like this one to treat advanced types of cancer are vital to ensure three in four people survive their disease by 2035.” – Dr Nigel Blackburn,

The study also did not meet its key secondary endpoints. Adverse events were generally balanced between Ace-ER and placebo and safety was consistent with previously released Ace-ER data.

Dravet Syndrome is a rare pediatric disease and lifelong form of epilepsy, which starts in the first year of life with frequent or prolonged seizures. Currently, the company